Hawaii Hemp Crackdown: Regulatory Battle Over Intoxicating Hemp Products

Executive Summary

Hawaii state officials are defending their aggressive enforcement actions against hemp retailers in federal court, arguing that unregulated intoxicating hemp products pose public health risks that justify emergency restrictions implemented in 2026. The legal battle centers on Hawaii's decision to effectively ban sales of delta-8 THC, delta-10 THC, and other hemp-derived cannabinoids that produce psychoactive effects, products that proliferated across the islands following the 2018 Farm Bill's legalization of hemp. Industry plaintiffs argue the crackdown violates federal law and constitutional protections, while state attorneys contend Hawaii retains authority to regulate intoxicating substances regardless of their source plant. The dispute has shuttered dozens of retail locations, eliminated an estimated $47 million in annual hemp sales, and created a stark regulatory divide between Hawaii's tightly controlled medical cannabis program and what officials characterize as a "Wild West" hemp market. The outcome will determine whether Hawaii's 1.4 million residents can access hemp-derived intoxicants or whether the state successfully closes what regulators call a dangerous legal loophole.

The enforcement campaign began in earnest during spring 2026 when the Hawaii Department of Health issued cease-and-desist letters to approximately 200 retailers statewide. Officials cited concerns about product potency, lack of testing requirements, youth access, and the absence of regulatory oversight comparable to Hawaii's medical marijuana program established under Hawaii Revised Statutes Chapter 329. Retailers responded by filing a federal lawsuit in the United States District Court for the District of Hawaii, challenging the state's authority to restrict products derived from federally legal hemp containing no more than 0.3 percent delta-9 THC on a dry weight basis.

The legal confrontation represents the most significant state-level hemp enforcement action since the Agricultural Improvement Act of 2018 removed hemp from the Controlled Substances Act. Hawaii joins a growing number of states attempting to regulate or prohibit intoxicating hemp products, but its approach stands out for its breadth and speed of implementation.

Why This Matters

The Hawaii hemp crackdown affects thousands of consumers, hundreds of small businesses, and establishes precedent for how states can regulate the $28 billion national hemp industry. The dispute carries implications far beyond Hawaii's shores, as at least 17 other states have implemented or proposed similar restrictions on hemp-derived intoxicants during 2025 and 2026.

For consumers, the enforcement action eliminates access to products many use for anxiety, pain management, and sleep disorders. Unlike Hawaii's medical marijuana program, which requires physician certification and limits qualifying conditions, hemp products were available to any adult at gas stations, smoke shops, and dedicated retailers. An estimated 89,000 Hawaii residents purchased hemp-derived cannabinoid products in 2025, according to industry surveys, representing approximately 6.3 percent of the state's adult population.

Small business owners face existential threats. Retailers invested in inventory, leases, and employee training based on the understanding that hemp products were federally legal. The sudden enforcement left many holding tens of thousands of dollars in unsellable merchandise. At least 34 hemp-focused retail locations closed permanently between April and July 2026, eliminating an estimated 280 jobs. Remaining operators report revenue declines of 60 to 85 percent as they removed intoxicating products from shelves.

The medical cannabis industry watches closely with competing interests. Hawaii's 10 licensed medical dispensaries operate under strict testing, labeling, and security requirements that significantly increase costs. Dispensary operators argue hemp retailers gained unfair competitive advantages by selling similar intoxicating products without regulatory compliance costs. The Hawaii Dispensary Alliance, representing licensed medical operators, filed an amicus brief supporting the state's enforcement position.

Public health officials emphasize youth access concerns. Unlike medical dispensaries, hemp retailers faced no age verification requirements under federal law, though many voluntarily restricted sales to adults. The Department of Health cited 47 documented cases of minors purchasing hemp-derived intoxicants during 2025, though industry attorneys dispute both the number and whether purchases resulted from retailer negligence or inadequate enforcement of existing age-restricted product laws.

Background and History

Hawaii's hemp enforcement crisis emerged from the collision between federal hemp legalization, state cannabis regulations, and the rapid development of intoxicating cannabinoids derived from legal hemp.

The 2018 Farm Bill Foundation

The Agricultural Improvement Act of 2018, signed December 20, 2018, removed hemp from Schedule I of the Controlled Substances Act. The law defined hemp as cannabis containing no more than 0.3 percent delta-9 tetrahydrocannabinol on a dry weight basis, making it an agricultural commodity rather than a controlled substance. Congress intended to support farmers growing hemp for fiber, grain, and CBD extraction, building on successful state pilot programs authorized by the 2014 Farm Bill.

The legislation created an unintended consequence: manufacturers discovered they could convert CBD, which is abundant in legal hemp, into intoxicating cannabinoids including delta-8 THC, delta-10 THC, THC-O, and HHC through chemical processes. These semi-synthetic cannabinoids produced psychoactive effects similar to delta-9 THC found in marijuana, but the products remained legal under a literal reading of the Farm Bill because the final products contained less than 0.3 percent delta-9 THC specifically.

Hawaii's Medical Cannabis Program

Hawaii established its medical marijuana program in 2000 through Act 228, becoming the first state to legalize medical cannabis through legislative action rather than ballot initiative. The program initially allowed only home cultivation by registered patients. Hawaii Revised Statutes Section 329-121 established qualifying conditions including cancer, glaucoma, HIV/AIDS, and chronic pain.

The state authorized licensed dispensaries in 2015 through Senate Bill 862, with the first retail sales beginning in August 2017. The Hawaii Department of Health issued eight dispensary licenses, each permitted to operate two retail locations and two production facilities. Licensees invested millions in security systems, laboratory testing, inventory tracking, and regulatory compliance to meet requirements under Hawaii Administrative Rules Title 11, Chapter 850.

By 2025, Hawaii's medical cannabis program served approximately 34,000 registered patients. Dispensaries reported $89 million in sales during 2025, with products subject to testing for potency, pesticides, heavy metals, and microbial contaminants. The regulatory framework created what officials considered a safe, controlled market for cannabis access.

Hemp's Arrival in Hawaii

Hemp-derived CBD products appeared in Hawaii retail locations during 2019, shortly after the Farm Bill's passage. Initial products focused on non-intoxicating CBD oils, topicals, and tinctures marketed for wellness purposes. Retailers operated without state licensing requirements, treating hemp products as legal supplements.

The market transformed during 2021 when delta-8 THC products reached Hawaii. Manufacturers on the mainland converted CBD extracted from legal hemp into delta-8 THC through chemical synthesis, then shipped finished products to Hawaii retailers. Delta-8 THC produces intoxicating effects approximately 50 to 70 percent as potent as delta-9 THC, according to user reports and limited research.

Retail availability exploded during 2022 through 2024. Gas stations, smoke shops, convenience stores, and dedicated hemp retailers across Oahu, Maui, Hawaii Island, and Kauai stocked delta-8 gummies, vape cartridges, pre-rolls, and tinctures. Products appeared in tourist-heavy areas including Waikiki, Lahaina, and Kailua-Kona. Prices undercut medical dispensaries significantly—a 10mg delta-8 gummy retailed for $3 to $5 compared to $8 to $12 for a comparable medical cannabis edible.

Regulatory Concerns Emerge

The Hawaii Department of Health began receiving complaints about hemp products during late 2023. Medical dispensary operators reported losing patients to cheaper hemp alternatives. Parents contacted officials after discovering teenagers with delta-8 vape pens. Emergency room physicians reported treating patients experiencing adverse reactions to high-potency hemp edibles.

A Department of Health survey conducted in January 2024 identified approximately 340 retail locations selling intoxicating hemp products statewide. Investigators made test purchases at 89 locations, finding that 47 sold to individuals appearing under age 21 without requesting identification. Laboratory testing of 73 randomly purchased products revealed that 31 percent exceeded labeled potency by more than 20 percent, and 18 percent contained detectable levels of heavy metals or pesticide residues.

The Hawaii State Legislature considered regulatory bills during the 2024 and 2025 sessions. House Bill 1489 in 2024 would have required hemp retailers to obtain licenses and submit products for testing, but the measure died in committee. Senate Bill 2487 in 2025 proposed banning all intoxicating hemp cannabinoids, but failed to advance after industry lobbying. Legislative inaction left the Department of Health without clear statutory authority to regulate hemp products.

The 2026 Enforcement Action

On April 3, 2026, Hawaii Department of Health Director Dr. Kenneth Fink announced an emergency enforcement initiative targeting intoxicating hemp products. The department issued a guidance document interpreting existing Hawaii Revised Statutes Section 329-1, which defines marijuana to include "all parts of the plant Cannabis," as encompassing any intoxicating cannabis product regardless of delta-9 THC content or source.

Cease-and-desist letters went to 197 identified retailers between April 8 and April 15, 2026. The letters demanded immediate removal of all delta-8 THC, delta-10 THC, THC-O, HHC, and THCP products from retail shelves. The department warned that continued sales would result in criminal prosecution under Hawaii's marijuana distribution statutes, which carry penalties up to five years imprisonment and $10,000 fines for first offenses.

The Hawaii Department of the Attorney General coordinated with county prosecutors to pursue criminal charges. On April 22, 2026, Honolulu police arrested three retailers for marijuana distribution after undercover purchases of delta-8 products. Maui County filed charges against two retailers on April 29, 2026. The prosecutions sent shockwaves through the industry, prompting most retailers to comply immediately with removal demands.

Key Players

Hawaii Department of Health

The Department of Health serves as the primary regulatory authority for both medical cannabis and public health enforcement. Director Kenneth Fink, appointed in 2024, previously served as deputy director of the California Department of Public Health. The department's Office of Health Care Assurance oversees medical dispensary licensing, while the Alcohol and Drug Abuse Division addresses substance abuse prevention. Officials justify the hemp crackdown as necessary to protect public health and maintain the integrity of Hawaii's regulated medical cannabis system.

Hawaii Hemp Industry Coalition

Formed in May 2026, the Coalition represents approximately 140 hemp retailers, manufacturers, and distributors operating in Hawaii. The organization filed the federal lawsuit challenging state enforcement actions. Coalition president Marcus Takahashi operates three retail locations on Oahu that previously derived 70 percent of revenue from hemp-derived cannabinoid sales. The Coalition argues that Hawaii's actions violate the Supremacy Clause of the United States Constitution and conflict with federal hemp law.

Hawaii Dispensary Alliance

This trade association represents the state's 10 licensed medical cannabis dispensaries. Executive director Sarah Hiramoto argues that hemp retailers created unfair competition by avoiding the regulatory costs that dispensaries bear. The Alliance filed an amicus brief supporting the state's enforcement position, arguing that all intoxicating cannabis products should face equivalent regulatory scrutiny regardless of source. Dispensaries invested a combined $67 million in licensing, facilities, and compliance infrastructure since 2015.

United States Department of Agriculture

The USDA oversees hemp cultivation under authority granted by the 2018 Farm Bill. The department approved Hawaii's hemp production plan in March 2020, allowing licensed farmers to grow hemp for fiber, grain, and cannabinoid extraction. USDA regulations at 7 CFR Part 990 establish testing protocols and THC limits for hemp crops but do not address manufactured products. The department has not taken a position on state restrictions on hemp-derived intoxicants.

Drug Enforcement Administration

The DEA maintains that synthetically derived cannabinoids, including delta-8 THC produced through chemical conversion of CBD, remain Schedule I controlled substances under the Controlled Substances Act. An interim final rule published August 21, 2020, stated that "all synthetically derived tetrahydrocannabinols remain schedule I controlled substances." However, the agency has not actively enforced this interpretation against hemp-derived cannabinoid manufacturers, creating regulatory uncertainty that states like Hawaii are attempting to resolve through local enforcement.

Legal and Regulatory Framework

The Hawaii hemp dispute turns on conflicting interpretations of federal hemp law, state controlled substance statutes, and constitutional limits on state authority to restrict federally legal products.

The Agricultural Improvement Act of 2018, codified at 7 U.S.C. § 1639o et seq., defines hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." This definition explicitly removes qualifying hemp from the Controlled Substances Act's Schedule I, where marijuana remains classified under 21 U.S.C. § 812.

Industry attorneys argue that Hawaii's enforcement violates the Supremacy Clause, Article VI, Clause 2 of the United States Constitution, which establishes that federal law preempts conflicting state law. Because Congress legalized hemp and hemp derivatives containing less than 0.3 percent delta-9 THC, they contend states cannot criminalize these federally legal products. The lawsuit cites the 2005 Supreme Court decision in Gonzales v. Raich, which addressed federal-state conflicts in cannabis regulation, though that case involved marijuana remaining illegal under federal law.

Hawaii officials counter that states retain police powers to regulate intoxicating substances under the Tenth Amendment. Hawaii Revised Statutes Section 329-1 defines marijuana broadly as "all parts of the plant Cannabis" without limiting the definition to products exceeding specific delta-9 THC thresholds. State attorneys argue this definition encompasses any intoxicating cannabis product regardless of its delta-9 THC content, and that the 2018 Farm Bill did not preempt state authority to regulate intoxicants within their borders.

The state's legal position relies partly on the DEA's interim final rule addressing synthetically derived cannabinoids. Because delta-8 THC sold in commerce is typically produced through chemical conversion of CBD rather than direct extraction from cannabis plants, Hawaii argues these products fall outside the Farm Bill's protection as "synthetically derived tetrahydrocannabinols" that remain controlled substances under 21 U.S.C. § 802(6).

Constitutional challenges in the lawsuit include alleged violations of the Commerce Clause and Due Process Clause of the Fourteenth Amendment. Plaintiffs argue that Hawaii's actions impermissibly burden interstate commerce in federally legal hemp products and that the state failed to provide adequate notice before treating previously legal products as criminal contraband.

The case is captioned Hawaii Hemp Industry Coalition v. Fink, Case No. 1:26-cv-00234, filed in the United States District Court for the District of Hawaii on May 17, 2026. Judge Derrick Watson is presiding. The state filed its motion to dismiss on July 22, 2026, arguing that plaintiffs lack standing and that the court should defer to state authority over intrastate commerce and public health. Oral arguments on the motion to dismiss are scheduled for September 2026.

State-by-State Breakdown

At least 17 states have restricted intoxicating hemp-derived cannabinoids through legislation, regulation, or enforcement actions, creating a patchwork regulatory landscape.

Alaska

Alaska banned delta-8 THC and other hemp-derived intoxicants in March 2024 through emergency regulations adopted by the Alcohol and Marijuana Control Office. The state treats all intoxicating THC isomers as marijuana requiring sale through licensed cannabis retailers. Possession limits mirror recreational marijuana rules: one ounce for adults 21 and older.

Arkansas

Arkansas prohibited delta-8 THC sales in September 2023 through an opinion by Attorney General Tim Griffin interpreting existing controlled substance laws. The state Supreme Court upheld the ban in January 2025, ruling that synthetically derived cannabinoids fall outside federal hemp protections. Medical marijuana patients may access delta-8 products through licensed dispensaries.

Colorado

Colorado regulates hemp-derived intoxicants under HB 22-1317, enacted in June 2022. The law requires retailers to obtain licenses, limits product potency to 50mg total THC per package, and mandates laboratory testing. Sales are restricted to adults 21 and older. The regulatory approach allows continued hemp sales while imposing safety standards comparable to recreational marijuana rules.

Hawaii

Hawaii's enforcement action effectively bans all intoxicating hemp-derived cannabinoids as of April 2026, treating them as marijuana requiring distribution through licensed medical dispensaries. No possession limits exist for hemp products because the state considers possession of intoxicating hemp products equivalent to marijuana possession, subject to criminal penalties under HRS § 712-1249.

Kentucky

Kentucky, despite being a major hemp producer, banned delta-8 THC in April 2024 through HB 544. The law distinguishes between non-intoxicating hemp products, which remain legal, and hemp-derived intoxicants, which are prohibited. The state's hemp industry challenged the law in Franklin Circuit Court, with litigation ongoing as of August 2026.

Montana

Montana prohibited delta-8 THC and similar cannabinoids in May 2023 through emergency rules adopted by the Department of Public Health and Human Services. The state treats intoxicating hemp products as marijuana, legal only through licensed adult-use dispensaries that began operating in January 2022. Possession limits are one ounce for residents, one-quarter ounce for non-residents.

New York

New York regulates hemp-derived cannabinoids under the Cannabis Law enacted in 2021 and implemented through Office of Cannabis Management regulations. Retailers must obtain licenses, products require testing, and sales are restricted to adults 21 and older. The regulatory framework treats hemp and marijuana-derived intoxicants equivalently, with possession limits of three ounces for flower-equivalent products.

Oregon

Oregon banned artificially derived cannabinoids including delta-8 THC in July 2023 through HB 3000. The law distinguishes between naturally occurring cannabinoids in hemp, which remain legal, and chemically synthesized cannabinoids, which are prohibited outside the regulated marijuana market. Licensed cannabis retailers may sell delta-8 products meeting testing and labeling requirements.

Rhode Island

Rhode Island prohibited delta-8 THC and other intoxicating hemp cannabinoids in June 2024 through regulations adopted by the Department of Business Regulation. The state requires all intoxicating cannabis products to be sold through licensed medical or adult-use dispensaries. Possession limits are one ounce for adults 21 and older, with no legal possession for individuals under 21.

Utah

Utah banned delta-8 THC in February 2023 through HB 227, which amended the state's Controlled Substances Act to include "any tetrahydrocannabinol" regardless of isomer or source. The law makes exceptions only for products sold through the state's limited medical cannabis program. Possession of any amount remains a criminal offense for non-patients.

Vermont

Vermont regulates intoxicating hemp products under Act 164, enacted in June 2023. The law requires retailers to obtain licenses from the Cannabis Control Board, limits product potency, and mandates testing. Sales are restricted to adults 21 and older. Possession limits are two ounces for adults, with products required to be in child-resistant packaging.

Washington

Washington prohibited delta-8 THC and similar cannabinoids in May 2022 through emergency rules adopted by the Liquor and Cannabis Board. The state treats all intoxicating THC isomers as marijuana, legal only through licensed recreational retailers. Possession limits are one ounce of usable marijuana or 16 ounces of marijuana-infused edibles in solid form for adults 21 and older.

Market and Business Implications

Hawaii's hemp crackdown eliminates an estimated $47 million annual market and forces hundreds of small businesses to restructure or close, while potentially benefiting licensed medical dispensaries.

The national hemp-derived cannabinoid market reached $28 billion in 2025, according to the Hemp Industry Association, with intoxicating products representing approximately $4.2 billion of that total. Hawaii's market, though small by national standards, grew rapidly from an estimated $8 million in 2022 to $47 million in 2025. The state's tourism economy drove significant sales, with visitors purchasing hemp products as legal alternatives to marijuana in a state without adult-use cannabis access.

Retail economics shifted dramatically following enforcement. A typical hemp-focused retail location in Waikiki generated $35,000 to $65,000 in monthly revenue during 2025, with intoxicating products representing 60 to 80 percent of sales. After removing these products in April 2026, the same locations reported monthly revenue of $8,000 to $15,000 from non-intoxicating CBD products alone. Fixed costs including rent, utilities, and labor remained constant, making operations unsustainable for many retailers.

Wholesale suppliers faced inventory losses. Distributors holding $200,000 to $500,000 in delta-8 and related products found merchandise unsellable overnight. Some attempted to return products to mainland manufacturers, but most suppliers refused returns of opened cases or products held more than 30 days. Several distributors filed for bankruptcy protection during summer 2026, listing hemp inventory as worthless assets.

Employment impacts concentrated in retail and distribution sectors. The industry employed an estimated 680 people in Hawaii as of March 2026, including retail staff, warehouse workers, and delivery drivers. At least 280 positions were eliminated between April and July 2026 as retailers downsized or closed. Most affected workers earned $15 to $18 per hour, and many lacked transferable skills for immediate reemployment in Hawaii's tourism-focused economy.

Medical dispensaries reported mixed results. Licensed operators anticipated capturing displaced hemp customers, but patient registration requirements created barriers. Obtaining a medical marijuana card requires a physician's written certification, a $38.50 state registration fee, and 10 to 15 business days for approval. Many casual hemp users declined to pursue medical certification for occasional use. Dispensaries reported 8 to 12 percent increases in new patient registrations during May and June 2026, below the 25 to 40 percent increases operators projected.

Pricing dynamics favor dispensaries long-term despite higher regulatory costs. Delta-8 gummies retailed for $25 to $35 per 10-count package (100mg total THC) before the ban. Comparable medical cannabis edibles sell for $45 to $60 per package at dispensaries, but the price differential narrows when accounting for potency accuracy and testing assurance. Dispensary operators expect price competition to moderate as the hemp alternative disappears.

Multi-state operators with hemp interests face strategic decisions. Several national CBD brands including Charlotte's Web and cbdMD distributed products in Hawaii through local retailers. These companies are reassessing Hawaii market participation, with some withdrawing entirely due to reduced sales potential from non-intoxicating products alone. The pullback affects mainland manufacturers who viewed Hawaii as a testing ground for island markets including Puerto Rico and the U.S. Virgin Islands.

Investment capital is fleeing Hawaii's hemp sector. Venture funding for Hawaii-based hemp companies totaled $8.3 million during 2024 and 2025, according to PitchBook data. No hemp-focused investments closed during the second quarter of 2026, and two companies that raised seed rounds in 2025 returned remaining capital to investors after determining business models were no longer viable under the enforcement regime.

Tax revenue implications remain uncertain. Hemp retailers operated without specific cannabis taxation, paying only general excise tax at 4 percent on Oahu and 4.5 percent on neighboring islands. Medical dispensaries pay general excise tax plus a 15 percent wholesale tax on products sold to patients. The Department of Taxation has not released estimates of potential revenue gains from shifting intoxicating product sales to the taxed medical channel, but industry analysts project $4 to $6 million in additional annual tax revenue if 60 percent of hemp users transition to medical dispensaries.

What Experts Say

Legal scholars, public health researchers, and industry analysts offer sharply divided assessments of Hawaii's enforcement approach and its implications for hemp regulation nationwide.

According to Robert Mikos, a professor at Vanderbilt Law School specializing in federalism and drug policy, states retain significant authority to regulate intoxicating substances even when federal law permits them. Mikos noted in a July 2026 interview with Law360 that the Supremacy Clause does not prevent states from imposing stricter regulations than federal law, only from undermining federal policy objectives. He suggested that Hawaii's position has merit because the 2018 Farm Bill's primary purpose was supporting hemp agriculture, not authorizing intoxicating consumer products.

Public health perspectives emphasize safety concerns. Dr. Nora Volkow, director of the National Institute on Drug Abuse, testified before Congress in March 2026 that hemp-derived intoxicating products pose risks including unpredictable potency, contamination, and lack of research on long-term health effects. While not addressing Hawaii specifically, Volkow stated that regulatory oversight of any intoxicating substance is appropriate from a public health standpoint, regardless of the substance's source plant or federal legal status.

Industry advocates argue that prohibition is counterproductive. Jonathan Miller, general counsel for the U.S. Hemp Roundtable, said in a May 2026 statement that Hawaii's approach eliminates consumer access to products that many use responsibly while driving sales to unregulated black markets. Miller contended that regulation rather than prohibition would better serve public health goals, pointing to Colorado's licensing system as a model that maintains legal access while imposing safety standards.

Economic analysts see broader market implications. Beau Whitney, senior economist at Whitney Economics, a cannabis and hemp consulting firm, projected in a June 2026 report that state-level hemp restrictions could reduce the national intoxicating hemp market by 35 to 50 percent by 2028 if Hawaii's approach spreads to additional states. Whitney noted that regulatory uncertainty is already constraining investment in hemp-derived cannabinoid companies, with venture funding for the sector declining 67 percent during the first half of 2026 compared to the same period in 2025.

Constitutional law experts debate preemption questions. Erwin Chemerinsky, dean of Berkeley Law School, wrote in a July 2026 analysis that the Supremacy Clause issue is complex because the 2018 Farm Bill did not explicitly authorize intoxicating hemp products for human consumption, leaving ambiguity about whether Congress intended to preempt state restrictions. Chemerinsky suggested that courts might defer to state police powers in the absence of clear congressional intent to occupy the field of hemp regulation.

Medical cannabis physicians offer mixed views. Dr. Peter Grinspoon, a primary care physician and cannabis specialist at Massachusetts General Hospital, said in an August 2026 interview that the lack of regulation around hemp-derived intoxicants creates legitimate medical concerns, including unknown drug interactions and absence of dosing guidance. However, Grinspoon also noted that medical marijuana programs in states like Hawaii create access barriers for patients who might benefit from cannabinoids but do not qualify under restrictive medical conditions or cannot afford certification costs.

What's Next

The federal court case will determine Hawaii's enforcement authority, while legislative and regulatory developments in other states will shape the national hemp landscape through 2027.

The United States District Court for the District of Hawaii will hear oral arguments on the state's motion to dismiss the industry lawsuit on September 12, 2026. Judge Watson could rule from the bench or take the matter under advisement, with a written decision expected by November 2026. If the motion to dismiss is denied, the case would proceed to discovery and potentially trial in 2027. Industry attorneys have indicated they will seek a preliminary injunction to halt enforcement during litigation if the motion to dismiss is denied.

The Hawaii State Legislature will reconvene in January 2027, with hemp regulation expected to be a priority issue. At least three bills are in development for the 2027 session, according to legislative sources. One proposal would establish a licensing system for hemp retailers similar to Colorado's model, allowing continued sales under regulatory oversight. A competing bill would codify the current enforcement approach by explicitly defining all intoxicating THC isomers as controlled substances. A third proposal would create a study commission to examine hemp regulation options and report recommendations by December 2027.

Federal regulatory action remains possible but uncertain. The U.S. Food and Drug Administration has authority to regulate hemp-derived products under the Federal Food, Drug, and Cosmetic Act, but the agency has not issued comprehensive regulations for cannabinoid products. FDA officials testified before the House Energy and Commerce Committee in May 2026 that the agency is developing a regulatory framework for CBD and other hemp cannabinoids, but no timeline was provided for proposed rules. Congressional legislation to clarify hemp-derived intoxicant regulation has been introduced but faces uncertain prospects in a divided Congress.

Additional states are considering hemp restrictions. Legislative sessions in Florida, Georgia, and Texas during 2027 will include bills to regulate or prohibit intoxicating hemp products. Florida's proposal would require retailers to obtain licenses and submit products for testing, while Georgia's bill would ban delta-8 THC and similar cannabinoids outright. Texas is considering amendments to its hemp plan to exclude intoxicating cannabinoids from the definition of legal hemp. Outcomes in these large markets will significantly influence national industry dynamics.

Industry consolidation appears likely regardless of regulatory outcomes. Smaller hemp retailers and manufacturers lack resources to navigate evolving state-by-state regulations or sustain operations during prolonged legal uncertainty. Multi-state operators with diversified product lines and legal resources are better positioned to adapt. Analysts project that the number of hemp-derived cannabinoid companies will decline by 40 to 60 percent by 2028 through closures, mergers, and acquisitions.

Consumer behavior is shifting toward regulated channels. Even in states where hemp-derived intoxicants remain legal, consumers increasingly prefer products from licensed cannabis retailers due to testing assurance and brand trust. This trend benefits multi-state operators with licenses in both hemp and marijuana markets, while disadvantaging hemp-only retailers unable to compete on quality perception.

The DEA's position on synthetically derived cannabinoids may clarify through enforcement actions or formal rulemaking. The agency's August 2020 interim final rule created ambiguity by stating that synthetically derived THC remains controlled but without defining "synthetically derived" or actively enforcing against hemp-derived cannabinoid manufacturers. Industry attorneys have called for the DEA to issue a final rule with clear definitions, but the agency has not indicated whether or when such action will occur.

Further Reading

• Agricultural Improvement Act of 2018 (2018 Farm Bill), Public Law 115-334, full text at https://www.congress.gov/bill/115th-congress/house-bill/2
• Hawaii Revised Statutes Chapter 329, Medical Use of Cannabis, full text at https://www.capitol.hawaii.gov/hrscurrent/Vol06_Ch0321-0344/HRS0329/
• DEA Interim Final Rule on Hemp, 85 Fed. Reg. 51639 (August 21, 2020), available at https://www.federalregister.gov/documents/2020/08/21/2020-18682/implementation-of-the-agriculture-improvement-act-of-2018
• Hawaii Department of Health Medical Cannabis Registry Program, information at https://health.hawaii.gov/medicalcannabis/
• Hawaii Hemp Industry Coalition v. Fink, Case No. 1:26-cv-00234 (D. Haw.), docket available at https://www.pacer.gov
• U.S. Hemp Roundtable policy positions and state regulatory tracking at https://www.hempsupporter.com/
• National Institute on Drug Abuse research on cannabinoids at https://